Wedbush raised the firm’s price target on Kura Oncology (KURA) to $38 from $36 and keeps an Outperform rating on the shares. The firm notes Ziftomenib at 600 mg QD dosing was approved in r/r NPM1m AML, ahead of the PDUFA date of November 30th. The approval was based on the KOMET-001 study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KURA: